ADMA Biologics Inc (ADMA) Expected to Announce Earnings of -$0.30 Per Share

Wall Street analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to post ($0.30) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have made estimates for ADMA Biologics’ earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.27). ADMA Biologics reported earnings of ($0.24) per share during the same quarter last year, which would indicate a negative year over year growth rate of 25%. The business is expected to issue its next earnings report on Monday, March 4th.

According to Zacks, analysts expect that ADMA Biologics will report full year earnings of ($1.37) per share for the current financial year, with EPS estimates ranging from ($1.42) to ($1.33). For the next fiscal year, analysts expect that the firm will report earnings of ($0.56) per share, with EPS estimates ranging from ($0.90) to ($0.10). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.02). The business had revenue of $4.23 million for the quarter, compared to the consensus estimate of $5.39 million. ADMA Biologics had a negative net margin of 243.42% and a negative return on equity of 155.19%.

Several research firms have recently issued reports on ADMA. Oppenheimer set a $13.00 price target on shares of ADMA Biologics and gave the company a “buy” rating in a research note on Tuesday, October 2nd. HC Wainwright set a $17.00 price target on shares of ADMA Biologics and gave the company a “buy” rating in a research note on Friday, November 9th. Raymond James reaffirmed a “buy” rating and set a $10.00 price target (down previously from $11.00) on shares of ADMA Biologics in a research note on Friday, October 12th. Finally, Maxim Group reaffirmed a “buy” rating and set a $12.00 price target on shares of ADMA Biologics in a research note on Wednesday, October 17th. Six research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of $11.58.

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of ADMA Biologics by 2,295.0% during the second quarter. BlackRock Inc. now owns 970,839 shares of the biotechnology company’s stock worth $4,378,000 after buying an additional 930,303 shares during the period. 683 Capital Management LLC increased its position in shares of ADMA Biologics by 9.9% during the second quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock worth $3,991,000 after buying an additional 80,000 shares during the period. AMP Capital Investors Ltd acquired a new stake in shares of ADMA Biologics during the second quarter worth $109,000. Renaissance Technologies LLC acquired a new stake in shares of ADMA Biologics during the second quarter worth $132,000. Finally, Ardsley Advisory Partners acquired a new stake in shares of ADMA Biologics during the second quarter worth $361,000. Institutional investors own 57.49% of the company’s stock.

Shares of ADMA stock traded down $0.13 during trading hours on Wednesday, hitting $3.22. 700 shares of the company’s stock traded hands, compared to its average volume of 321,650. The company has a market capitalization of $158.52 million, a P/E ratio of -1.69 and a beta of 2.84. ADMA Biologics has a 12 month low of $2.08 and a 12 month high of $6.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 4.92 and a current ratio of 6.32.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Story: Cost of Equity

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit